Financial Survey: INC Research (NASDAQ:SYNH) versus Its Rivals

INC Research (NASDAQ: SYNH) is one of 191 public companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its competitors? We will compare INC Research to similar companies based on the strength of its dividends, profitability, institutional ownership, analyst recommendations, risk, earnings and valuation.

Profitability

This table compares INC Research and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
INC Research -4.29% 14.42% 5.17%
INC Research Competitors -4,393.69% -464.44% -41.50%

Analyst Recommendations

This is a summary of recent recommendations and price targets for INC Research and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
INC Research 0 4 6 0 2.60
INC Research Competitors 712 2625 6952 146 2.63

INC Research currently has a consensus price target of $49.88, suggesting a potential upside of 38.35%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 22.87%. Given INC Research’s higher probable upside, equities research analysts plainly believe INC Research is more favorable than its competitors.

Institutional and Insider Ownership

97.3% of INC Research shares are held by institutional investors. Comparatively, 48.6% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 0.2% of INC Research shares are held by company insiders. Comparatively, 14.7% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

INC Research has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500. Comparatively, INC Research’s competitors have a beta of 1.53, meaning that their average stock price is 53% more volatile than the S&P 500.

Earnings and Valuation

This table compares INC Research and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
INC Research $1.61 billion $112.63 million -62.15
INC Research Competitors $227.13 million -$38.54 million -48.29

INC Research has higher revenue and earnings than its competitors. INC Research is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

INC Research beats its competitors on 7 of the 13 factors compared.

About INC Research

Syneos Health, Inc., formerly INC Research Holdings, Inc., is a global contract research organization (CRO). The Company focuses on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services. The Company’s Clinical Development Services segment offers a range of clinical development services, including full-service global studies, as well as ancillary services, such as clinical monitoring, investigator recruitment, patient recruitment, data management, study reports to assist customers with their drug development process, quality assurance audits and specialized consulting services. The Phase I Services segment focuses on clinical development services for Phase I trials, which include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds.

Receive News & Ratings for INC Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INC Research and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply